Trial Profile
PROMO: A Phase II Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- Acronyms PROMO
- 01 Sep 2021 Primary endpoint (Clinical benefit rate) has not been met, according to Results published in the Cancer Immunology Immunotherapy.
- 01 Sep 2021 Results published in the Cancer Immunology Immunotherapy
- 15 Oct 2020 According to clinicaltrials.gov the study was stopped because less than 2 patients had clinical benefit.